Nishiyama M, Takagami S, Kirihara Y, Saeki T, Niimi K, Nosoh Y, Hirabayashi N, Niimoto M, Hattori T
Department of Surgery, Hiroshima University, Japan.
Jpn J Surg. 1988 Nov;18(6):647-52. doi: 10.1007/BF02471525.
In order to determine the indications of chemosensitivity tests against various anticancer agents, clinical trials of 4 different assays, namely; nude mouse isotope assay (NMIA), subrenal capsule assay (SRCA), human tumor clonogenic assay (HTCA) and adenosine triphosphate inhibition assay (ATPA), were performed on 391 patients. Analysis of the correlation between assay results and clinical effects presented the possibility of determining the indications as follows; (1) The positive clinical response of mitomycin C (MMC) should be predicted by ATPA; (2) The clinical tumor resistance against MMC should be predicted by SRCA; (3) Concerning 5-fluorouracil (5-FU) the chemosensitivity test (ATPA) should only be used for the detection of tumor resistance in the assay; (4) The poor results of this study indicated the difficulty of correctly estimating the effects of cyclophosphamide (CPM); (5) The perfect prediction of clinical effects in this trial indicated that cis-DDPlatinum (CDDP) should be estimated by SRCA; (6) The positive clinical tumor response against adriamycin (ADM) should be predicted by SRCA, while the negative one should be predicted by HTCA; and (7) ATPA showed good potential for estimating not only time dependent drugs such as 5-FU, but also cytotoxic drugs.
为了确定针对各种抗癌药物的化学敏感性试验的适应症，对391例患者进行了4种不同检测方法的临床试验，即裸鼠同位素检测法（NMIA）、肾包膜下检测法（SRCA）、人肿瘤克隆形成检测法（HTCA）和三磷酸腺苷抑制检测法（ATPA）。分析检测结果与临床疗效之间的相关性，得出如下确定适应症的可能性：（1）丝裂霉素C（MMC）的阳性临床反应应由ATPA预测；（2）MMC的临床肿瘤耐药性应由SRCA预测；（3）对于5-氟尿嘧啶（5-FU），化学敏感性试验（ATPA）仅应用于检测该检测中的肿瘤耐药性；（4）本研究结果不佳表明正确评估环磷酰胺（CPM）效果存在困难；（5）本试验中对临床疗效的完美预测表明顺铂（CDDP）应由SRCA评估；（6）阿霉素（ADM）的阳性临床肿瘤反应应由SRCA预测，而阴性反应应由HTCA预测；（7）ATPA不仅在评估如5-FU等时间依赖性药物方面，而且在评估细胞毒性药物方面都显示出良好的潜力。
